Summit Therapeutics (SMMT) Gains from Investment Securities (2020)
Summit Therapeutics' (SMMT) quarterly Gains from Investment Securities came in at -$1000.0 in Q4 2020, little changed on a QoQ basis from -$1000.0 in Q3 2020.
Powered by 
Analysis
Summit Therapeutics (SMMT) Gains from Investment Securities (2020) Analysis & Trends
Summit Therapeutics (SMMT) has 1 years of Gains from Investment Securities data on file, last reported at -$1000.0 in Q4 2020.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$1000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2021 was -$2000.0 (changed N/A YoY) and the FY2020 annual result came in at -$102000.0, down 5200.0% from the prior year.
- Gains from Investment Securities held at -$1000.0 in Q4 2020, from -$1000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of -$1000.0 in Q3 2020 to a low of -$1000.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 13.67 Bn | 12.98 Bn | - |